SUBSCRIBE
SUBSCRIBE

Johnson & Johnson Family of Companies

NEWS
3 Biotechs That Could be Taken Out This Quarter
Deals
Rumor Mill: Johnson & Johnson, Novartis AG and Takeda are All Making Googly Eyes at This Brazilian Drugmaker
April 25, 2017
 · 
3 min read
Johnson & Johnson Dissolves $700 Million R&D Deal With MacroGenics
Business
Johnson & Johnson Hosts ‘Shark-Tank'-Like Competition and Crowned This Biotech Startup as Its Winner
April 19, 2017
 · 
2 min read
Business
Johnson & Johnson’s Weak Pharma Revenue Could Spell Doom For Rest Of Sector
April 19, 2017
 · 
1 min read
Johnson & Johnson Dissolves $700 Million R&D Deal With MacroGenics
Business
Johnson & Johnson Forges Peptide Discovery Pact Worth $1.5 Billion With Japanese Biopharma Peptidream
April 7, 2017
 · 
2 min read
Pharm Country
Here’s Why The Best Is Yet To Come For Johnson & Johnson
April 4, 2017
 · 
1 min read
Pharm Country
Worried About Johnson & Johnson’s Valuation? Consider This Crazy, Undervalued, 4.2% Yielding Pharmaceutical Stock Instead
March 30, 2017
 · 
1 min read
Policy
Senator Launches Investigation Into Top Opioid Makers—Purdue Pharma L.P., Janssen/Johnson & Johnson, INSYS, Mylan And Depomed
March 29, 2017
 · 
1 min read
Johnson & Johnson Dissolves $700 Million R&D Deal With MacroGenics
Job Trends
Johnson & Johnson’s $100,000 Anti-Burnout Program for Top Execs
March 27, 2017
 · 
3 min read
Business
Johnson & Johnson, GlaxoSmithKline Yank Ads From YouTube
March 23, 2017
 · 
1 min read
Load More
AWARDS
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
JOBS
IN THE PRESS
Press Releases
European Commission approves TREMFYA® (guselkumab) for the treatment of children with plaque psoriasis, marking the first paediatric indication for an IL-23 inhibitor
December 22, 2025
 · 
14 min read
Press Releases
Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma
December 19, 2025
 · 
6 min read
Press Releases
U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)
December 18, 2025
 · 
33 min read
Press Releases
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results - December 15, 2025
December 16, 2025
 · 
1 min read
Press Releases
Link Cell Therapies Launches with Vision of Advancing CAR-T Therapies in Solid and Liquid Tumors
December 16, 2025
 · 
4 min read
Press Releases
U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*
December 15, 2025
 · 
20 min read
Press Releases
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI®▼ (teclistamab) plus DARZALEX® (daratumumab) subcutaneous formulation as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
December 10, 2025
 · 
18 min read
Press Releases
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
December 10, 2025
 · 
28 min read
Press Releases
Johnson & Johnson to Participate in the 44th Annual J.P. Morgan Healthcare Conference
December 9, 2025
 · 
1 min read
Press Releases
Earlier use of CARVYKTI®▼ (ciltacabtagene autoleucel) demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
December 8, 2025
 · 
15 min read
Load More